Part 1/7:
Gilead Sciences Faces Headwinds Despite Dividend Increase
Gilead Sciences, a giant in the biotech industry often compared to Apple for its transformative impact, reported a challenging first quarter that has raised concerns among investors and analysts alike. While the company announced an increase in its quarterly dividend—a positive signal to shareholders—its financial results painted a different picture, highlighting ongoing struggles in revenue growth and profitability.